- The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy.
- The prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Palonosetron HCl 0.25 mg
Up to 18 Years
Use in patients younger than 18 is not recommended until further data is available.
18 Years Old and Above
250 micrograms palonosetron as single intravenous bolus.
Applied approximately 30 minutes before the start of chemotherapy. Palonosetron should be injected over 30 seconds.
Repeated dosing of palonosetron within a seven day interval is not recommended. The efficacy of palonosetron in the prevention of nausea and vomiting induced by highly emetogenic chemotherapy may be enhanced by the addition of corticosteroid administered prior to chemotherapy.
No dose adjustment is necessary for the elderly.
Patients with Hepatic Impairment
No dose adjustment is necessary for patients with impaired hepatic function.
Patients with Renal Impairment
No dose adjustment is necessary for patients with impaired renal function. No data are available for patients with end stage renal disease undergoing hemodialysis.